Deborah Lang, PhD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine

PhD, Drexel University College of Medicine
BS, Philadelphia University

Dr. Lang, appointed as an Associate Professor of Dermatology, was recruited from the University of Chicago. Here at BU, she will continue her basic science research mission focusing on the molecular and cellular biology of melanoma. The lab’s research is centered on studying processes that occur during pigment cell development of the embryo and applying these findings toward melanoma. The premise is that pathways that are essential for development (such as growth, survival, and migration) are also important for melanoma progression (over-growth, inappropriate survival, and metastasis). She has mentored over twenty students and has served as an elected council member and plenary speaker of the Pan American Society for Pigment Cell Research.

Boston University
BU-BMC Cancer Center

Melanocyte stem cell lineage determination and plasticity
02/01/2022 - 01/31/2025 (PI)
LEO Foundation

Regulation of the melanocyte lineage by the AP2 transcription factor family
01/01/2022 - 07/31/2023 (Subcontract PI)
University of Washington NIH NIAMS

Transcriptional Mechanisms underlying the shared and unique roles of YAP and TAZ in melanoma
06/01/2020 - 05/31/2022 (PI)
Harry J. Lloyd Charitable Trust

Regulation of the melanocyte lineage by the AP2 transcription factor family
08/26/2018 - 12/31/2021 (Subcontract PI)
The University of Iowa NIH NIAMS

10/01/2016 - 07/31/2021 (PI)
NIH/National Cancer Institute

Daneen & Charles Stifel Investigative Scientist Award
05/01/2018 - 04/30/2020 (PI)
American Skin Association


Yr Title Project-Sub Proj Pubs
2019 PAX3 pathways in melanoma 5R01CA184001-06 5
2018 PAX3 pathways in melanoma 5R01CA184001-05 5
2017 PAX3 pathways in melanoma 5R01CA184001-04 5
2016 PAX3 pathways in melanoma 7R01CA184001-03 5
2016 PAX3 pathways in melanoma 5R01CA184001-02 5
2015 PAX3 pathways in melanoma 1R01CA184001-01A1 5
2013 Pax3, Melanocyte Stem Cells and Melanoma 5R01CA130202-05 11
2012 Pax3, Melanocyte Stem Cells and Melanoma 5R01CA130202-04 11
2011 Pax3, Melanocyte Stem Cells and Melanoma 5R01CA130202-03 11
2010 Pax3, Melanocyte Stem Cells and Melanoma 5R01CA130202-02 11
Showing 10 of 11 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Vittoria MA, Kingston N, Kotynkova K, Xia E, Hong R, Huang L, McDonald S, Tilston-Lunel A, Darp R, Campbell JD, Lang D, Xu X, Ceol CJ, Varelas X, Ganem NJ. Inactivation of the Hippo tumor suppressor pathway promotes melanoma. Nat Commun. 2022 Jun 29; 13(1):3732.View Related Profiles. PMID: 35768444; PMCID: PMC9243107; DOI: 10.1038/s41467-022-31399-w;
  2. Huang L, Zhai Y, Fajardo CD, Lang D. YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model. Cancers (Basel). 2021 Dec 29; 14(1). PMID: 35008307; PMCID: PMC8749984; DOI: 10.3390/cancers14010143;
  3. Lui JW, Moore SPG, Huang L, Ogomori K, Li Y, Lang D. YAP facilitates melanoma migration through regulation of actin-related protein 2/3 complex subunit 5 (ARPC5). Pigment Cell Melanoma Res. 2022 01; 35(1):52-65. PMID: 34468072; PMCID: PMC8958630; DOI: 10.1111/pcmr.13013;
  4. Huang L, Zhai Y, La J, Lui JW, Moore SPG, Little EC, Xiao S, Haresi AJ, Brem C, Bhawan J, Lang D. Targeting Pan-ETS Factors Inhibits Melanoma Progression. Cancer Res. 2021 04 15; 81(8):2071-2085.View Related Profiles. PMID: 33526511; PMCID: PMC8137525; DOI: 10.1158/0008-5472.CAN-19-1668;
  5. Zhai Y, Haresi AJ, Huang L, Lang D. Differences in tumor initiation and progression of melanoma in the BrafCA ;Tyr-CreERT2;Ptenf/f model between male and female mice. Pigment Cell Melanoma Res. 2020 01; 33(1):119-121. PMID: 31449725; PMCID: PMC6928400; DOI: 10.1111/pcmr.12821;
  6. Lui JW, Xiao S, Ogomori K, Hammarstedt JE, Little EC, Lang D. The Efficiency of Verteporfin as a Therapeutic Option in Pre-Clinical Models of Melanoma. J Cancer. 2019; 10(1):1-10. PMID: 30662519; PMCID: PMC6329844; DOI: 10.7150/jca.27472;
  7. Little EC, Kubic JD, Salgia R, Grippo PJ, Lang D. Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. Oncol Lett. 2017 Jun; 13(6):4027-4034. PMID: 28588695; PMCID: PMC5452919; DOI: 10.3892/ol.2017.5956;
  8. Kubic JD, Little EC, Kaiser RS, Young KP, Lang D. FOXD3 Promotes PAX3 Expression in Melanoma Cells. J Cell Biochem. 2016 Feb; 117(2):533-41. PMID: 26252164; PMCID: PMC4887145; DOI: 10.1002/jcb.25306;
  9. Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 04; 290(36):21901-14. PMID: 26205821; PMCID: PMC4571945; DOI: 10.1074/jbc.M115.670976;
  10. Kubic JD, Little EC, Lui JW, Iizuka T, Lang D. PAX3 and ETS1 synergistically activate MET expression in melanoma cells. Oncogene. 2015 Sep 17; 34(38):4964-74. PMID: 25531327; PMCID: PMC4476961; DOI: 10.1038/onc.2014.420;
Showing 10 of 32 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 32 publications over 20 distinct years, with a maximum of 4 publications in 2009

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

molecular biology
gene transcription
transcription factors
Contact for Mentoring:

609 Albany Street
Boston MA 02115
Google Map

Lang's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department